Prenatal hamster development following maternal administration of PGE2 at midterm.
The effects of PGE2 on embryonic and fetal development were studied in the golden Syrian hamster. Pregnant hamsters were treated on day 8 of gestation with either 0.2, 0.5, 0.75, or 1.0 mg/kg PGE2 delivered I.P. and the near term litters were compared to those of untreated and vehicle treated controls. Fetuses from the treated litters showed significantly higher frequencies of mortality, lower weights, malformations, and missing ossification centres in comparison to control litters. The results demonstrate that PGE2 is teratogenic in the hamster and the developing neural tube and the fetal skeleton are particularly susceptible to the effects of this teratogen.
D000014:Abnormalities, Drug-Induced / Q000209:etiology* / Q000473:pathology; D000818:Animals; D001724:Birth Weight / Q000187:drug effects; D001846:Bone Development / Q000187:drug effects; D006224:Cricetinae; D015232:Dinoprostone; D005260:Female; D005313:Fetal Death / Q000139:chemically induced; D008647:Mesocricetus; D009436:Neural Tube Defects / Q000139:chemically induced; D011247:Pregnancy; D011270:Pregnancy, Animal / Q000187:drug effects*; D011458:Prostaglandins E / Q000633:toxicity*
D011458:Prostaglandins E; D015232:Dinoprostone